



Cite this: DOI: 10.1039/d6cc90175a

## Correction: Phenylboronic acid-modified nanoparticles for cancer treatment


 Siming Zhou,<sup>a</sup> Liqun Dai,<sup>a</sup> Lili Pan,<sup>b</sup> Guohua Shen<sup>\*b</sup> and Zhiyong Qian<sup>\*a</sup>

 Correction for 'Phenylboronic acid-modified nanoparticles for cancer treatment' by Siming Zhou *et al.*, *Chem. Commun.*, 2025, **61**, 4595–4605, DOI: [10.1039/D4CC06730D](https://doi.org/10.1039/D4CC06730D).

DOI: 10.1039/d6cc90175a

[rsc.li/chemcomm](https://rsc.li/chemcomm)

The authors regret that the caption to Fig. 1, also used as the graphical abstract image, did not correctly indicate that it was adapted from a figure originally published in *Acc. Chem. Res.*, 2019, 52(11), 3108–3119, cited as ref. 13 in the original article.<sup>1</sup> The updated figure and caption are shown below.



**Fig. 1** A schematic illustration of boronic acids acting as ligands for diols such as (A) reduced pH, (B) ROS, (C) reacting with diols, and (D) sialic acid. This figure was adapted from ref. 13 with permission. Copyright 2019, American Chemical Society.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

## References

- 1 A. Stubelius, S. Lee and A. Almutairi, *Acc. Chem. Res.*, 2019, **52**, 3108–3119.

<sup>a</sup> Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.  
E-mail: zhiyongqian@scu.edu.cn

<sup>b</sup> Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.  
E-mail: shengh1990@126.com

